In Vitro Activity of a New Quinoline Derivative, ER-2, against Clinical Isolates of Mycoplasma pneumoniae and Mycoplasma hominis▿
AUTOR(ES)
Rao, Shilpakala Sainath
FONTE
American Society for Microbiology (ASM)
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2786322Documentos Relacionados
- In Vitro Activity of Telithromycin (HMR3647), a New Ketolide, against Clinical Isolates of Mycoplasma pneumoniae in Japan
- In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.
- In Vitro Activities of DU-1102, a New Trioxaquine Derivative, against Plasmodium falciparum Isolates
- In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
- Activity of SM-4470, a new imidazole derivative, against experimental fungal infections.